IP Library Granted Patent US 12,064,620
Granted Patent B2
US 12,064,620 · App. 18/317,715 · Granted Aug 20, 2024

Neural stimulation dosing

Inventor: John Louis Parker (Artarmon, AU)
Assignee: Saluda Medical Pty Ltd
A61N1/0551A61N1/05A61N1/06A61N1/3605A61N1/36071A61N1/36146A61N1/36171A61N1/36175A61N1/36178A61N1/36185A61N1/37247A61N1/36021
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,064,620
App. No.
18/317,715
Granted
Aug 20, 2024
Kind
B2
Abstract

Applying therapeutic neural stimuli involves monitoring for at least one of sensory input and movement of a user. In response to detection of sensory input or user movement, an increased stimulus dosage is delivered within a period of time corresponding to a duration of time for which the detected sensory input or user movement gives rise to masking, the increased stimulus dosage being configured to give rise to increased neural recruitment.

Claims (30)

1. A method of applying therapeutic neural stimuli, the method comprising:

monitoring, by a control unit, for at least one of sensory input and movement of a user by measuring neural activity upon a neural pathway of the user with at least one electrode positioned alongside the neural pathway; and

applying, by the control unit, therapeutic neural stimuli to the neural pathway with the at least one electrode based on the at least one of sensory input and movement of the user,

wherein the measured neural activity comprises non-evoked neural activity.

2. The method of claim 1 , wherein the monitoring comprises directly measuring an amplitude of the non-evoked neural activity by determining the maximum and minimum values of the non-evoked neural activity over a window.

3. The method of claim 1 , wherein the monitoring comprises directly measuring an amplitude of the non-evoked neural activity by determining a root mean square of the non-evoked neural activity over a window.

4. The method of claim 1 , wherein the monitoring comprises directly measuring an amplitude of the non-evoked neural activity until a threshold measure of activity is reached.

5. The method of claim 4 , wherein the threshold measure of activity is set such that it is above a base line of non-evoked activity with the user at rest.

6. The method of claim 1 , wherein the applying comprises, in response to detection of at least one of sensory input and a user movement, delivering an increased stimulus dosage within a period of time corresponding to a duration of time for which the detected sensory input or user movement gives rise to masking, the increased stimulus dosage being configured to give rise to increased neural recruitment.

7. The method of claim 6 , wherein the increased stimulus dosage is effected by increasing one or more of an amplitude of the neural stimuli, a pulse width of the neural stimuli, and a frequency of the neural stimuli.

8. The method of claim 7 , wherein the increased stimulus dosage comprises a burst of high frequency stimuli.

9. The method of claim 7 , wherein at times when neither sensory input nor movement is detected, stimuli are delivered at a reduced dosage.

10. The method of claim 6 , wherein at times when neither sensory input nor movement is detected, no stimuli are delivered.

11. The method of claim 6 , further comprising:

monitoring a cumulative stimulus dosage delivered to the user, and

using the cumulative stimulus dosage as a basis to define a required stimulus regime either during or between movements in order to deliver a desired total stimulus dosage.

12. The method of claim 6 , wherein the period of time within which the increased stimulus dosage is delivered is a predefined approximation of the duration of a typical human movement.

13. The method of claim 6 , wherein the period of time for which the increased stimulus dosage is delivered is adaptively determined by performing the further step of detecting a cessation of sensory input or movement by the user, and in turn ceasing the delivery of the increased stimulus dosage.

14. The method of claim 6 , wherein the increased stimulus dosage is delivered at select moments within the period of time.

15. A device for applying therapeutic neural stimuli, the device comprising:

at least one electrode configured to be positioned alongside a neural pathway of a user; and

a control unit configured to:

monitor for at least one of sensory input and movement of the user by measuring neural activity upon a neural pathway of the user, and

apply therapeutic neural stimuli to the neural pathway based on the at least one of sensory input and movement of the user,

wherein the measured neural activity comprises non-evoked neural activity.

16. The device of claim 15 , wherein the control unit is configured to monitor by directly measuring an amplitude of the non-evoked neural activity by determining the maximum and minimum values of the non-evoked neural activity over a window.

17. The device of claim 15 , wherein the control unit is configured to monitor by directly measuring an amplitude of the non-evoked neural activity by determining a root mean square of the non-evoked neural activity over a window.

18. The device of claim 15 , wherein the control unit is configured to monitor by directly measuring an amplitude of the non-evoked neural activity until a threshold measure of activity is reached.

19. The device of claim 15 , wherein the control unit is configured to apply the therapeutic stimuli by, in response to detection of at least one of sensory input and a user movement, delivering an increased stimulus dosage via the at least one electrode within a period of time corresponding to a duration of time for which the detected sensory input or user movement gives rise to masking, the increased stimulus dosage being configured to give rise to increased neural recruitment.

20. The device of claim 19 , wherein the control unit is configured to effect the increased stimulus dosage by increasing one or more of an amplitude of the neural stimuli, a pulse width of the neural stimuli, and a frequency of the neural stimuli.

Assignments (2)
SECURITY INTEREST Recorded Mar 14, 2025
From: SALUDA MEDICAL PTY LTD
To: PERCEPTIVE CREDIT HOLDINGS IV, LP
Reel/Frame 070518/0710 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2024
From: PARKER, JOHN LOUIS
To: SALUDA MEDICAL PTY LTD
Reel/Frame 066448/0841 →
Priority Claims (2)
AU 2014902897 · Jul 25, 2014 · national
AU 2015900912 · Mar 13, 2015 · national
Continuity (4)
Continuation 17234678 · Apr 19, 2021
Continuation 16823296 · Mar 18, 2020
Continuation 15327981
Related Publication 20230364417A1 · Nov 16, 2023